McKesson Corporation (MCK) Enterprise Value (EV): $90.28B
The enterprise value (EV) for McKesson Corporation (MCK) is $90.28B as of Friday, June 19, 2026.
MCK Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$90.28B
MCK Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| McKesson Corporation (MCK) | $87.88B | $90.28B |
| Elevance Health Inc. (ELV)vs › | $84.37B | $101.50B |
| HCA Healthcare, Inc. (HCA)vs › | $83.23B | $156.87B |
| Medtronic plc (MDT)vs › | $101.86B | $132.81B |
| Cigna Corporation (CI)vs › | $73.88B | $96.98B |
| Boston Scientific Corporation (BSX)vs › | $67.35B | $151.53B |
| Bristol-Myers Squibb Company (BMY)vs › | $110.27B | $147.02B |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $62.84B | $80.33B |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $114.63B | $114.72B |
| Stryker Corporation (SYK)vs › | $119.03B | $146.68B |
Enterprise Value Calculation
Market Cap
$87.88B
Total Debt
$6.37B
Cash
$3.98B
Enterprise Value
$90.28B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
McKesson Corporation Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
McKesson Corporation Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for McKesson Corporation (MCK)?
- The enterprise value (EV) for MCK stock is $90.28B.
Related Metrics
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler